Proprotein convertase subtilisin/kexin 9 (PCSK9), one of the serine proteases ... data (treatment-emergent adverse events, clinical chemical analyses, and hematologic measurements) are provided ...

"Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels," by Nabil Seidah et al, was published in the January issue of Molecular Metabolism.

Many cholesterol medications lower LDL, some of them by targeting the protein PCSK9. In the January issue ... About the American Society for Biochemistry and Molecular Biology: The ASBMB is ...

PHILADELPHIA -- (Nov. 15, 2018) -- Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating ...

In the last 10 years, PCSK9 emerged as a promising target for the treatment of autosomal dominant hypercholesterolemia (ADH). With the emergence of induced pluripotent stem (hiPS) cells and following ...

A recently discovered means of decreasing PCSK9 levels is the administration of small interfering RNA (siRNA) molecules. 15 The siRNA molecules engage the natural pathway of RNA interference (RNAi ...

Using the technique, the firm’s scientists obtained multiple cyclic peptides in the 1,000–2,000 molecular weight range that bind strongly to PCSK9. Unfortunately, they showed poor permeability ...

A new oral formulation of a PCSK9-inhibitor, cholesterol-lowering drug in development by Merck has shown encouraging results in a phase 2 study. The study was presented by Christie Ballantyne, MD ...

More information: Makan Khoshnejad et al, Development of Novel DNA-Encoded PCSK9 Monoclonal Antibodies as Lipid-Lowering Therapeutics, Molecular Therapy (2018). DOI: 10.1016/j.ymthe.2018.10.016 ...